


congestive heart failure, renal failure, atherosclerosis, conditions of reduced blood vessel patency, peripheral vascular disease, vascular disorders, systemic sclerosis (SSc), scleroderma, morphea, inflammatory diseases, stroke, bronchitis, chronic asthma, allergic asthma, allergic rhinitis, diabetic neuropathy, Idiopathic pulmonary fibrosis (IPF), peyronic's disease, glaucoma or a disease characterized by disorders of gut motility like irritable bowel syndrome, liver fibrosis, Alzheimer's disease and chronic heart failure, wherein further preferably said disease is selected from wound healing, chronic wound healing, diabetic foot, diabetic foot ulcer, leg ulcer, diabetic neuropathy, peripheral vascular disease, vascular disorders, Raynaud's disease, systemic sclerosis (SSc), scleroderma, diabetes, pulmonary artery hypertension, male erectile dysfunction, and wherein again further preferably said disease is selected from wound healing, chronic wound healing, diabetic foot, diabetic foot ulcer, leg ulcer and diabetic neuropathy.

In another aspect, the present disclosure provides for use of the compound of formula **I** as defined herein, or the pharmaceutical composition as defined herein, or a pharmaceutically acceptable salt, solvate or hydrate thereof in the manufacture of a medicament for treating a disease selected from the group consisting of wound healing, chronic wound healing, diabetic foot, diabetic foot ulcer, leg ulcer, Raynaud's disease, male erectile dysfunction, female sexual dysfunction, vascular aging, pulmonary artery hypertension; stable, unstable and variant (Prinzmetal) angina; hypertension, pulmonary hypertension, chronic obstructive pulmonary disease, congestive heart failure, renal failure, atherosclerosis, conditions of reduced blood vessel patency, peripheral vascular disease, vascular disorders, systemic sclerosis (SSc), scleroderma, morphea, inflammatory diseases, stroke, bronchitis, chronic asthma, allergic asthma, allergic rhinitis, diabetic neuropathy, Idiopathic pulmonary fibrosis (IPF), peyronic's disease, glaucoma or a disease characterized by disorders of gut motility like irritable bowel syndrome, liver fibrosis, Alzheimer's disease and chronic heart failure, wherein preferably said disease is selected from wound healing, chronic wound healing, diabetic foot, diabetic foot ulcer, leg ulcer, diabetic neuropathy, peripheral vascular disease, vascular disorders such as Raynaud's disease, systemic sclerosis (SSc), scleroderma, pulmonary artery hypertension, male erectile dysfunction, and wherein again further preferably said disease is selected from wound healing, chronic wound healing, diabetic foot, diabetic foot ulcer, leg ulcer and diabetic neuropathy.

CLAIMS:

1. A compound of formula I



or pharmaceutically acceptable salt, solvate or hydrate thereof, wherein

R₁ is C₁-C₃alkyl optionally substituted with F, C₃-C₆cycloalkyl, C₁-C₃alkoxy;

X-R₂ represents C₁-C₃alkylene substituted with ONO, ONO₂, CN, C(O)OH, C(O)OC₁-C₃alkyl, C(O)N(R₆)OR₇, CHO, OC(O)H, OC₁-C₃alkylene-C(O)OH, OC₁-C₃alkylene-C(O)N(R₆)OR₇,
10 OC(O)-C₁-C₃alkyl, CR₈=N-OR₉; C(O)OC₁-C₃alkyl, CHO, C(O)N(R₆)OR₇, S(O₀₋₂)C₁-C₃alkyl, CR₈=N-OR₉, CR₈=N-NR₁₀R₁₁, CR₈=NR₁₂ or CR₈=N-ONO₂;

R₃ is C₁-C₆alkyl optionally substituted with F, OH, ONO, ONO₂, C₁-C₃alkoxy, C₃-C₆cycloalkyl; C₃-C₆cycloalkyl, C₂-C₆alkenyl, C₂-C₆alkynyl;

R₄ is C₁-C₆alkyl optionally substituted with C₃-C₆cycloalkyl, C₁-C₆alkoxy, F, ONO, ONO₂; C₂-
15 C₆alkenyl, C₂-C₆alkynyl, C₃-C₆cycloalkyl;

R₅ is SO₂NR₁₃R₁₄, NHSO₂NR₁₃R₁₄;

R₆ is H or C₁-C₃alkyl;

R₇ is H, C₁-C₃alkyl, C₁-C₃alkoxy, C₁-C₃alkyl substituted with phenyl, benzyl or a heterocyclic ring, wherein said phenyl, benzyl or said heterocyclic ring are independently optionally
20 substituted by C₁-C₃alkyl, F;

R₈ is H, CH₃ or C₂H₅;

R₉ is H, C₁-C₃alkyl optionally substituted with OH, ONO, ONO₂, CN, COOH, COOC₁-C₃alkyl, C₁-C₃alkoxy, OC(O)H, OC(O)-C₁-C₃alkyl, C(O)N(R₆)OR₇, OC₁-C₃alkylene-C(O)OH, OC₁-C₃alkylene-C(O)OC₁-C₃alkyl, OC₁-C₃alkylene-C(O)N(R₆)OR₇, S(O₀₋₂)C₁-C₃alkyl;

R₁₀ and R₁₁ are each independently H, C₁-C₃alkyl optionally substituted with OH, ONO, ONO₂, CN, COOH, COOC₁-C₃, C₁-C₃alkoxy, OC(O)H, OC(O)-C₁-C₃alkyl, C(O)N(R₆)OR₇, OC₁-C₃alkylene-C(O)OH, OC₁-C₃alkylene-C(O)OC₁-C₃alkyl, OC₁-C₃alkylene-C(O)N(R₆)OR₇, S(O₀-

₂)C₁-C₃alkyl; or together with the nitrogen atom to which they are attached form a heterocyclic ring, wherein preferably said heterocyclic ring is selected from aziridine, azetidine, pyrrolidine, piperidine, morpholine, piperazine and homopiperazine, wherein said heterocyclic ring is optionally substituted with C₁-C₃ alkyl;

5 R₁₂ is C₁-C₃ alkyl optionally substituted with OH, ONO, ONO₂, CN, COOH, COOC₁-C₃alkyl, C₁-C₃alkoxy, OC(O)H, OC(O)-C₁-C₃alkyl, C(O)N(R₆)OR₇, OC₁-C₃alkylene-C(O)OH, OC₁-C₃alkylene-C(O)OC₁-C₃alkyl, OC₁-C₃alkylene-C(O)N(R₆)OR₇, S(O₀₋₂)C₁-C₃alkyl;

R₁₃ and R₁₄ are each independently H or C₁-C₆alkyl optionally substituted with F, OH, ONO, ONO₂, COOH, C₁-C₃alkoxy, C₃-C₆cycloalkyl; or together with the nitrogen atom to which they
10 are attached form a heterocyclic ring, wherein preferably said heterocyclic ring is selected from aziridine, azetidine, pyrrolidine, piperidine, morpholine, piperazine, homopiperazine, 2,5-diazabicyclo[2,2,1]heptane and 3,7-diazabicyclo[3,3,0]octane, wherein said heterocyclic ring is optionally substituted with R₁₅;

R₁₅ is C₁-C₆alkyl optionally substituted with halogen, OH, ONO, ONO₂, C₁-C₃alkoxy, C₁-
15 C₃haloalkoxy, COOR₁₆, NR₁₇R₁₈, C=NR₁₉, or with a tetrazole group which is optionally substituted with C₁-C₃alkyl; or a heteroaryl ring which is optionally substituted with F, wherein the at least one heteroatom of said heteroaryl ring is nitrogen;

R₁₆ is H, or C₁-C₄alkyl optionally substituted with F, OH, ONO, ONO₂, NR₁₇R₁₈, or with a heteroaryl ring, wherein the at least one heteroatom of said heteroaryl ring is nitrogen, and
20 wherein preferably said heteroaryl ring is selected from pyrrolidine, piperidine, piperazine, morpholine, pyrrole, and imidazole, wherein nitrogen atom is directly bound to C₁-C₄ alkyl;

R₁₇ and R₁₈ are each independently H or C₁-C₄alkyl optionally substituted with ONO, ONO₂;

R₁₉ is C₁-C₄alkyl optionally substituted with F, ONO, ONO₂; C₃-C₆cycloalkyl.

25 2. The compound according to claim 1 or pharmaceutically acceptable salt, solvate or hydrate thereof, wherein R₁ is C₁-C₃alkyl.

3. The compound according to any one of the claims 1 to 2, or pharmaceutically acceptable salt, solvate or hydrate thereof, wherein R₃ is C₁-C₄alkyl optionally substituted with F, OH, ONO, ONO₂, C₁-C₃alkoxy, C₃-C₆cycloalkyl, C₂-C₄alkenyl.
30

4. The compound according to any one of the claims 1 to 3, or pharmaceutically acceptable salt, solvate or hydrate thereof, wherein R₄ is C₁-C₄alkyl optionally substituted with C₃-C₆cycloalkyl, C₁-C₃alkoxy, F, ONO, ONO₂; C₂-C₄alkenyl.

5. The compound according to any one of claims 1 to 4, or pharmaceutically acceptable salt, solvate or hydrate thereof, wherein

R₁₃ and R₁₄ together with the nitrogen atom to which they are attached form a heterocyclic ring, wherein said heterocyclic ring is selected from aziridine, azetidine, pyrrolidine, piperidine, morpholine, piperazine, homopiperazine, 2,5-diazabicyclo-[2,2,1]heptane and 3,7-diazabicyclo[3,3,0]octane, wherein said heterocyclic ring is optionally substituted with R₁₅;

R₁₅ is C₁-C₄alkyl optionally substituted with halogen, OH, ONO, ONO₂, C₁-C₃alkoxy, C₁-C₃haloalkoxy, COOR₁₆, NR₁₇R₁₈, C=NR₁₉;

10 R₁₆ is H, or C₁-C₄alkyl optionally substituted with F, OH, ONO, ONO₂;

R₁₇ and R₁₈ are each independently H or C₁-C₄alkyl optionally substituted with ONO, ONO₂;

R₁₉ is C₁-C₄alkyl optionally substituted with F, ONO, ONO₂.

6. The compound according to any one of claims 1 to 5, or pharmaceutically acceptable salt, solvate or hydrate thereof, wherein

15 X-R₂ represents C₁-C₃alkylene substituted with CN, C(O)OH, C(O)OC₁-C₃alkyl, C(O)N(R₆)OR₇, CHO, OC(O)H, OC₁-C₃alkylene-C(O)OH, OC₁-C₃alkylene-C(O)N(R₆)OR₇, OC(O)-C₁-C₃alkyl, CR₈=N-OR₉; C(O)OC₁-C₃alkyl, CHO, C(O)N(R₆)OR₇, S(O₀₋₂)C₁-C₃alkyl, CR₈=N-OR₉, CR₈=N-NR₁₀R₁₁, CR₈=NR₁₂ or CR₈=N-ONO₂, wherein preferably said R₈ is H or
20 CH₃, and again further preferably wherein said R₆ is H or CH₃.

7. The compound according to any one of claims 1 to 6, or pharmaceutically acceptable salt, solvate or hydrate thereof, wherein

X-R₂ represents C₁-C₃alkylene substituted with CN, C(O)OH, C(O)OC₁-C₃alkyl, C(O)N(R₆)OR₇,
25 CHO, OC(O)H, OC₁-C₃alkylene-C(O)OH, OC₁-C₃alkylene-C(O)N(R₆)OR₇, OC(O)-C₁-C₃alkyl, CR₈=N-OR₉; C(O)OC₁-C₃alkyl, CHO, C(O)N(R₆)OR₇, CR₈=N-OR₉.

8. The compound according to any one of claims 1 to 7, or pharmaceutically acceptable salt, solvate or hydrate thereof, wherein X-R₂ represents CR₈=N-OR₉, wherein said R₈ is H or CH₃,
30 and wherein said R₉ is H or C₁-C₃ alkyl optionally substituted with OH.

9. The compound according to any one of claims 1 to 8, or pharmaceutically acceptable salt, solvate or hydrate thereof, wherein X-R₂ represents (*E*)-CR₈=N-OR₉, wherein said R₈ is H or CH₃, and wherein said R₉ is H or C₁-C₃ alkyl optionally substituted with OH.

10. The compound according to claim 1 or pharmaceutically acceptable salt, solvate or hydrate thereof, wherein said compound is selected from
- (*E*)-2-(2-ethoxy-5-((4-methylpiperazin-1-yl)sulfonyl)phenyl)-5-methyl-4-oxo-7-propyl-3,4-dihydropyrrolo[2,1-*f*][1,2,4]triazine-6-carbaldehyde oxime (**1a**);
- 5 2-(2-ethoxy-5-((4-methylpiperazin-1-yl)sulfonyl)phenyl)-5-methyl-4-oxo-7-propyl-3,4-dihydropyrrolo[2,1-*f*][1,2,4]triazine-6-yl)methyl acetate (**1c**);
- 2-(2-ethoxy-5-((4-methylpiperazin-1-yl)sulfonyl)phenyl)-5-methyl-4-oxo-7-propyl-3,4-dihydropyrrolo[2,1-*f*][1,2,4]triazine-6-carboxylic acid (**1d**);
- 10 N-(benzyloxy)-2-(2-ethoxy-5-((4-methylpiperazin-1-yl)sulfonyl)phenyl)-5-methyl-4-oxo-7-propyl-3,4-dihydropyrrolo[2,1-*f*][1,2,4]triazine-6-carboxamide (**1e**);
- Methyl 2-(2-ethoxy-5-((4-methylpiperazin-1-yl)sulfonyl)phenyl)-5-methyl-4-oxo-7-propyl-3,4-dihydropyrrolo[2,1-*f*][1,2,4]triazine-6-carboxylate (**1f**);
- 2-(2-ethoxy-5-((4-methylpiperazin-1-yl)sulfonyl)phenyl)-N-hydroxy-5-methyl-4-oxo-7-propyl-3,4-dihydropyrrolo[2,1-*f*][1,2,4]triazine-6-carboxamide (**1g**);
- 15 2-((2-(2-ethoxy-5-((4-methylpiperazin-1-yl)sulfonyl)phenyl)-5-methyl-4-oxo-7-propyl-3,4-dihydropyrrolo[2,1-*f*][1,2,4]triazine-6-yl)methoxy)acetic acid (**1h**);
- 2-((2-(2-ethoxy-5-((4-methylpiperazin-1-yl)sulfonyl)phenyl)-5-methyl-4-oxo-7-propyl-3,4-dihydropyrrolo[2,1-*f*][1,2,4]triazine-6-yl)methoxy)-N-hydroxy-N-methylacetamide (**1i**);
- 20 2-(2-ethoxy-5-((4-methylpiperazin-1-yl)sulfonyl)phenyl)-5-methyl-4-oxo-7-propyl-3,4-dihydropyrrolo[2,1-*f*][1,2,4]triazine-6-carbaldehyde (**1j**);
- 5-methyl-2-(5-((4-methylpiperazin-1-yl)sulfonyl)-2-propoxyphenyl)-4-oxo-7-propyl-3,4-dihydropyrrolo[2,1-*f*][1,2,4]triazine-6-carbaldehyde (**1l**);
- 2-(5-((4-(2-hydroxyethyl)piperazin-1-yl)sulfonyl)-2-propoxyphenyl)-5-methyl-4-oxo-7-propyl-3,4-dihydropyrrolo[2,1-*f*][1,2,4]triazine-6-carbaldehyde (**1m**);
- 25 (*E*)-5-methyl-2-(5-((4-methylpiperazin-1-yl)sulfonyl)-2-propoxyphenyl)-4-oxo-7-propyl-3,4-dihydropyrrolo[2,1-*f*][1,2,4]triazine-6-carbaldehyde O-methyl oxime (**1o**);
- 2-(5-((4-(2-hydroxyethyl)piperidin-1-yl)sulfonyl)-2-propoxyphenyl)-5-methyl-4-oxo-7-propyl-3,4-dihydropyrrolo[2,1-*f*][1,2,4]triazine-6-carbaldehyde (**1p**);
- 30 2-(1-((3-(6-formyl-5-methyl-4-oxo-7-propyl-3,4-dihydropyrrolo[2,1-*f*][1,2,4]triazin-2-yl)-4-propoxyphenyl)sulfonyl)piperidin-4-yl)ethyl nitrate (**1q**);
- (*E*)-2-(5-((4-(2-hydroxyethyl)piperidin-1-yl)sulfonyl)-2-propoxyphenyl)-5-methyl-4-oxo-7-propyl-3,4-dihydropyrrolo[2,1-*f*][1,2,4]triazine-6-carbaldehyde oxime (**1r**);

- ethyl-3-(2-(2-ethoxy-5-((4-methylpiperazin-1-yl)sulfonyl)phenyl)-5-methyl-4-oxo-7-propyl-3,4-dihydropyrrolo[2,1-f][1,2,4]triazin-6-yl)-3-hydroxypropanoate (**1s**);
- 3-(2-(2-ethoxy-5-((4-methylpiperazin-1-yl)sulfonyl)phenyl)-5-methyl-4-oxo-7-propyl-3,4-dihydropyrrolo[2,1-f][1,2,4]triazin-6-yl)-N,3-dihydroxypropanamide (**1t**);
- 5 3-(2-(2-ethoxy-5-((4-methylpiperazin-1-yl)sulfonyl)phenyl)-5-methyl-4-oxo-7-propyl-3,4-dihydropyrrolo[2,1-f][1,2,4]triazin-6-yl)-3-hydroxypropanenitrile (**1u**);
- (*E*)-2-(1-((3-(6-((hydroxyimino)methyl)-5-methyl-4-oxo-7-propyl-3,4-dihydropyrrolo[2,1-f][1,2,4]triazin-2-yl)-4-propoxyphenyl)sulfonyl)piperidin-4-yl)ethyl nitrate (**1v**);
- 2-(2-ethoxy-5-((4-(2-hydroxyethyl)piperazin-1-yl)sulfonyl)phenyl)-5-methyl-4-oxo-7-propyl-3,4-dihydropyrrolo[2,1-f][1,2,4]triazine-6-carbaldehyde(**1w**);
- 10 (*E*)-2-(2-ethoxy-5-((4-(2-hydroxyethyl)piperazin-1-yl)sulfonyl)phenyl)-5-methyl-4-oxo-7-propyl-3,4-dihydropyrrolo[2,1-f][1,2,4]triazine-6-carbaldehyde oxime (**1x**);
- 2-(2-ethoxy-5-((4-(2-hydroxyethyl)piperazin-1-yl)sulfonyl)phenyl)-5-methyl-4-oxo-7-propyl-3,4-dihydropyrrolo[2,1-f][1,2,4]triazine-6-carbaldehyde O-methyloxime (**1y**);
- 15 (*E*)-2-(2-ethoxy-5-((4-(2-hydroxyethyl)piperazin-1-yl)sulfonyl)phenyl)-5-methyl-4-oxo-7-propyl-3,4-dihydropyrrolo[2,1-f][1,2,4]triazine-6-carbaldehyde O-(2-hydroxyethyl) oxime (**1z**);
- 2-(2-ethoxy-5-((4-(2-hydroxyethyl)piperazin-1-yl)sulfonyl)phenyl)-5-ethyl-4-oxo-7-propyl-3,4-dihydropyrrolo[2,1-f][1,2,4]triazine-6-carbaldehyde(**1aa**);
- (*E*)-2-(2-ethoxy-5-((4-(2-hydroxyethyl)piperazin-1-yl)sulfonyl)phenyl)-5-ethyl-4-oxo-7-propyl-3,4-dihydropyrrolo[2,1-f][1,2,4]triazine-6-carbaldehyde oxime (**1ab**);
- 20 (*E*)-2-(2-ethoxy-5-((4-(2-hydroxyethyl)piperazin-1-yl)sulfonyl)phenyl)-5-ethyl-4-oxo-7-propyl-3,4-dihydropyrrolo[2,1-f][1,2,4]triazine-6-carbaldehyde O-methyl oxime (**1ac**);
- (*E*)-2-(2-ethoxy-5-((4-(2-hydroxyethyl)piperazin-1-yl)sulfonyl)phenyl)-5-ethyl-4-oxo-7-propyl-3,4-dihydropyrrolo[2,1-f][1,2,4]triazine-6-carbaldehyde O-(2-hydroxyethyl) oxime (**1ad**);
- 25 2-(4-((4-ethoxy-3-(6-formyl-5-methyl-4-oxo-7-propyl-3,4-dihydropyrrolo[2,1-f][1,2,4]triazin-2-yl)phenyl)sulfonyl)piperazin-1-yl)ethyl nitrate (**1ae**);
- (*E*)-2-(4-((4-ethoxy-3-(6-((hydroxyimino)methyl)-5-methyl-4-oxo-7-propyl-3,4-dihydropyrrolo[2,1-f][1,2,4]triazin-2-yl)phenyl)sulfonyl)piperazin-1-yl)ethyl nitrate (**1af**);
- 2-(4-((4-ethoxy-3-(5-ethyl-6-formyl-4-oxo-7-propyl-3,4-dihydropyrrolo[2,1-f][1,2,4]triazin-2-yl)phenyl)sulfonyl)piperazin-1-yl)ethyl nitrate (**1ag**);
- 30 (*E*)-2-(4-((4-ethoxy-3-(5-ethyl-6-((hydroxyimino)methyl)-4-oxo-7-propyl-3,4-dihydropyrrolo[2,1-f][1,2,4]triazin-2-yl)phenyl)sulfonyl)piperazin-1-yl)ethyl nitrate (**1ah**);
- (*E*)-2-(4-((4-ethoxy-3-(6-((methoxyimino)methyl)-5-methyl-4-oxo-7-propyl-3,4-dihydropyrrolo[2,1-f][1,2,4]triazin-2-yl)phenyl)sulfonyl)piperazin-1-yl)ethyl nitrate (**1ai**);

(*E*)-2-(4-((4-ethoxy-3-(6-(((2-hydroxyethoxy)imino)methyl)-5-methyl-4-oxo-7-propyl-3,4-dihydropyrrolo[2,1-*f*][1,2,4]triazin-2-yl)phenyl)sulfonyl)piperazin-1-yl)ethyl nitrate (**1ak**);

(*E*)-2-(2-ethoxy-5-((4-(2-hydroxyethyl)piperidin-1-yl)sulfonyl)phenyl)-5-methyl-4-oxo-7-propyl-3,4-dihydropyrrolo[2,1-*f*][1,2,4]triazine-6-carbaldehyde oxime (**1al**);

5 (*E*)-2-(1-((4-ethoxy-3-(6-((hydroxyimino)methyl)-5-methyl-4-oxo-7-propyl-3,4-dihydropyrrolo[2,1-*f*][1,2,4]triazin-2-yl)phenyl)sulfonyl)piperidin-4-yl)ethyl nitrate (**1am**);

(*E*)-2-(2-ethoxy-5-((4-(3-hydroxypropyl)piperazin-1-yl)sulfonyl)phenyl)-5-methyl-4-oxo-7-propyl-3,4-dihydropyrrolo[2,1-*f*][1,2,4]triazine-6-carbaldehyde oxime (**1an**);

10 (*E*)-3-(4-((4-ethoxy-3-(6-((hydroxyimino)methyl)-5-methyl-4-oxo-7-propyl-3,4-dihydropyrrolo[2,1-*f*][1,2,4]triazin-2-yl)phenyl)sulfonyl)piperazin-1-yl)propyl nitrate (**1ao**);
and

(*Z*)-2-(1-((3-(6-((hydroxyimino)methyl)-5-methyl-4-oxo-7-propyl-3,4-dihydropyrrolo[2,1-*f*][1,2,4]triazin-2-yl)-4-propoxyphenyl)sulfonyl)piperidin-4-yl)ethyl nitrate (**1aq**).

15 11. The compound according to claim 1 or pharmaceutically acceptable salt, solvate or hydrate thereof, wherein said compound is selected from

(*E*)-2-(5-((4-(2-hydroxyethyl)piperidin-1-yl)sulfonyl)-2-propoxyphenyl)-5-methyl-4-oxo-7-propyl-3,4-dihydropyrrolo[2,1-*f*][1,2,4]triazine-6-carbaldehyde oxime (**1r**); and

20 (*E*)-2-(1-((3-(6-((hydroxyimino)methyl)-5-methyl-4-oxo-7-propyl-3,4-dihydropyrrolo[2,1-*f*][1,2,4]triazin-2-yl)-4-propoxyphenyl)sulfonyl)piperidin-4-yl)ethyl nitrate (**1v**).


12. A pharmaceutical composition comprising at least one of the compound of formula **I** of any one of the claims 1 to 11, or a pharmaceutically acceptable salt, solvate or hydrate thereof, and a pharmaceutically acceptable excipient, adjuvant, or carrier.

25 13. The compound of formula **I** of any one of the claims 1 to 11, or the pharmaceutical composition of claim 12, or a pharmaceutically acceptable salt, solvate or hydrate thereof, for use as a medicament.

30 14. Use of the compound of formula **I** of any one of the claims 1 to 11, or the pharmaceutical composition of claim 12, or a pharmaceutically acceptable salt, solvate or hydrate thereof in the manufacture of a medicament for treating a disease selected from the group consisting of wound healing, chronic wound healing, diabetic foot, diabetic foot ulcer, leg ulcer, Raynaud's disease, male erectile dysfunction, female sexual dysfunction, vascular aging, pulmonary artery
35 hypertension; stable, unstable and variant (Prinzmetal) angina; hypertension, pulmonary hypertension, chronic obstructive pulmonary disease, congestive heart failure, renal failure,


atherosclerosis, conditions of reduced blood vessel patency, peripheral vascular disease, vascular disorders, systemic sclerosis (SSc), scleroderma, morphea, inflammatory diseases, stroke, bronchitis, chronic asthma, allergic asthma, allergic rhinitis, diabetic neuropathy, Idiopathic pulmonary fibrosis (IPF), peyronic's disease, glaucoma or a disease characterized by disorders of gut motility like irritable bowel syndrome, liver fibrosis, Alzheimer's disease and chronic heart failure, wherein preferably said disease is selected from wound healing, chronic wound healing, diabetic foot, diabetic foot ulcer, leg ulcer, diabetic neuropathy, peripheral vascular disease, vascular disorders such as Raynaud's disease, systemic sclerosis (SSc), scleroderma, pulmonary artery hypertension, male erectile dysfunction, and wherein again further preferably said disease is selected from wound healing, chronic wound healing, diabetic foot, diabetic foot ulcer, leg ulcer and diabetic neuropathy.

15. A compound of formula **IV**




15 wherein X, R₁, R₂, R₃, R₄, R₅ are defined as for the compound of formula **I** in any one of the claims 1 to 8.

16. A process for the preparation of a compound of formula **I** of any one of the claims 1 to 11,



wherein said process comprises:


(a) reaction of a compound of formula **II** with a benzoic acid derivative of formula **III** in an aprotic or a protic solvent to generate a compound of formula **IV**



(b) cyclization of said compound of formula **IV** to yield compound of formula **I**,


wherein X, R₁, R₂, R₃, R₄, and R₅ are defined as for the compound of formula **I** in any one of the claims 1 to 11.

17. A process for the preparation of a compound of formula **I** of any one of the claims 1 to 11,




wherein said process comprises


(a) reaction of a compound of formula **VI** with a benzoyl chloride derivative of formula **VIA** to generate a compound of formula **VII**



(b) hydrolysis of the ester compound of formula **VII** to an acid derivative of formula **VIII**



(c) amination of said compound of formula **VIII** to yield a compound of formula **IV**



5 (d) cyclization of said compound of formula **IV** to yield compound of formula **I**,

wherein X, R₁, R₂, R₃, R₄, and R₅ are defined as for the compound of formula **I** in any one of the claims 1 to 8; and

wherein R' is C₁-C₄ alkyl, benzyl, 4-alkoxybenzyl.